20-Jul-2026
Zymeworks to Report Second Quarter 2026 Financial Results on August 6, 2026
Globe Newswire (Thu, 16-Jul 6:00 AM ET)
PRNewswire (Mon, 6-Jul 11:20 AM ET)
Zymeworks to Acquire Theravance Biopharma, Inc.
Globe Newswire (Mon, 29-Jun 6:00 AM ET)
Gandeeva and Zymeworks Use Cryo-EM to Accelerate Antibody Drug Discovery
PRNewswire (Thu, 18-Jun 8:00 AM ET)
Globe Newswire (Sun, 14-Jun 6:05 PM ET)
Zymeworks Announces Share Repurchase Program of up to $125 Million of its Common Stock
Globe Newswire (Thu, 14-May 4:05 PM ET)
Zymeworks Announces Participation in Upcoming Investor Conferences
Globe Newswire (Wed, 13-May 6:00 AM ET)
Zymeworks Provides Corporate Update and Reports First Quarter 2026 Financial Results
Globe Newswire (Thu, 7-May 4:05 PM ET)
Globe Newswire (Tue, 21-Apr 5:30 PM ET)
Market Chameleon (Mon, 30-Mar 3:53 AM ET)
Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Its suite of therapeutic platforms and its fully integrated drug development engine enables precise engineering of differentiated therapeutic product candidates. Its clinical candidate, zanidatamab, is a novel HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. It is also advancing a deep preclinical pipeline in oncology and other therapeutic areas.
Zymeworks trades on the NASDAQ stock market under the symbol ZYME.
As of July 20, 2026, ZYME stock price declined to $23.76 with 411,818 million shares trading.
ZYME has a beta of 0.19, meaning it tends to be less sensitive to market movements. ZYME has a correlation of 0.00 to the broad based SPY ETF.
ZYME has a market cap of $1.75 billion. This is considered a Small Cap stock.
Last quarter Zymeworks reported $2 million in Revenue and -$.59 earnings per share. This fell short of revenue expectation by $-35 million and missed earnings estimates by -$.49.
In the last 3 years, ZYME traded as high as $29.75 and as low as $6.02.
The top ETF exchange traded funds that ZYME belongs to (by Net Assets): VTI, IWM, IBB, IWO, VTWO.
ZYME has outperformed the market in the last year with a return of +64.1%, while the SPY ETF gained +19.4%. However, in the most recent history, ZYME shares have underperformed the stock market with its stock returning -14.5% in the last 3 month period and -9.7% for the last 2 week period, while SPY has returned +4.8% and -0.4%, respectively.
ZYME support price is $23.39 and resistance is $24.99 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that ZYME shares will trade within this expected range on the day.